pfizer metsera pfe mtsr stock share price: Pfizer PFE stock, Metsera MTSR stock: Pfizer, Metsera share prices jump as deal worth over $7 billion gets thumbs up

On Monday, Pfizer Stock (NYSE: PFE) and Metsera Stock (Nasdaq: MTSR) are treated hot at the New York Stock Exchange and Nasdaq. The Pfizer Inc stock price rose to $ 24.50 and the METERA stock price rose to $ 54.34. Pfizer Inc. While the markets were opened on Monday, the shares of Metsera advanced approximately 61 percent.

The stock market explosion for both companies’ shares said Pfizer on Monday that he would buy a drug developer Metsera with an agreement up to $ 7.3 billion, including future payments, as he aims to gain a basis in the rapid growing obesity treatment market. The global obesity pharmaceutical market, which is expected to reach $ 150 billion until the beginning of the 2030s, is fueled by the rapid adoption of GLP-1 therapies from companies such as Novo Nordisk and Eli Lilly. Drug producers are competing to develop new generation treatments, including hormones that can help patients lose fat while protecting muscle.

Pfizer said on Monday that the development phase will pay $ 47.50 in cash for each share of drug producer Metsera. This creates more than 42 percent premiums for Metsera’s closing price on Friday. Pfizer may also pay an additional $ 22.50 per share depending on how the product pipeline of Metsera develops.
METSERA INC. has no product in the market, but the pipeline contains a program in four and middle stage tests in clinical development. Pfizer said the agreement will add expertise and potential verbal and injectable treatments. Pfizer CEO Albert Bourla, the drug producer said in a statement, “a large and growing area,” he calls the obesity of more than 200 health conditions, he said.

Novo Nordisk and Eli Lilly and Co.’s Zepbound demanded obesity treatments due to unprecedented weight loss provided by regular market leaders Wegovy injections. The Lilly medicine sold $ 5.7 billion in the first half of the year. However, drugs can cost patients hundreds of dollars a month, and experts in this field are looking for competition to potentially reduce prices.

Pfizer currently has no obesity treatment in the market, but there are some of the clinical development. Earlier this year, the company said that the largest and most expensive stage of clinical development ended the development of pill treatment once a day before starting the late stage test. Companies are waiting for the purchase to close in the fourth quarter of this year. The organizers still need approval.

FAQ

Quarter. What do we know about Pfizer-Metera to agree?
A1. This, Pfizer’s statement on Monday, aims to gain a basis in the rapidly growing obesity treatment market, including future payments, including an agreement up to $ 7.3 billion, including the drug developer Metsera’yı said.

S2. Does Pfizer have obesity treatments?
A2. Pfizer currently has no obesity treatment in the market, but there are some of the clinical development. Earlier this year, the company said it ended the development of pill treatment once a day before starting the late stage test, the largest and most expensive stage of clinical development.